Team GIRAUDIER & MASLAH
Normal and Pathological Myeloid HematopoiesisLearn more about the team
Chronic myeloid disorders (MPN, MDS): Clonal selection, microenvironment models and functions, therapeutic targeting.
The team 6 led by Pr. S. Giraudier is also a member of the Institut de la Leucémie Paris Saint-Louis.
See details below in the research axes.
Axes explorés
Axis 1: Mechanisms of leukemic cell identity, vulnerabilities, and stress adaptation
Sub-axis 1.1: Cellular heterogeneity and molecular determinants
Functional in vitro analysis of JAK2 missense variants
Contact: Diego Elrio, Emmanuelle Verger, Bruno Cassinat
Sub-axis 1.2: Intrinsic vulnerabilities of malignant cells
Improving therapeutic efficacy in myeloproliferative neoplasms through a combined pro-senescence and senolytic strategy
Contact : Nabih Maslah, Duanya Liu
Sub-axis 1.3: Cellular consequences of therapeutic stress
Hydroxyurea promotes clonal selection of TP53-mutated cells in myeloproliferative neoplasms
Contact : Nabih Maslah, Bruno Cassinat, Jean-Jacques Kiladjian
Mechanisms of action of Interferon in myeloproliferative neoplasms
Contact : Stéphane Giraudier, Duanya Liu
Sub-axis 1.4: Hematopoietic stem cell stress responses
Study of the hematopoietic stress response under physiological and pathological conditions (myeloproliferative neoplasms) using an induced anemia model
Contact : Stéphane Giraudier, Duanya Liu
Axis 2: Leukemic stem cells and microenvironmental ecosystems
This axis explores the interactions between leukemic cells and their microenvironment (stroma, vascular niche, immune system). It aims to understand how these interactions sustain disease, modulate treatment responses, and evolve under the effect of stressors such as inflammation or hypoxia, drawing in particular on spatial biology approaches and innovative models.
Sub-axis 2.1: Pathological bone marrow ecosystem
Study of the microenvironment in patients with myelofibrosis
Contact : Sarah Awan-Toor, Bruno Cassinat
Sous-axe 2.2 : Niche vasculaire et organisation spatiale
Analysis of the bone marrow vascular niche in patients with myeloproliferative neoplasms using spatial biology approaches
Contact : Laura Velazquez
Sub-axis 2.2: Vascular niche and spatial organization
(Including humanized murine models, organoids, organs-on-a-chip – projects to be specified)
Contact: Sarah Awan-Toor, Bruno Cassinat, Nabih Maslah
Axis 3: Precision medicine – therapeutic targets, combinations, and biomarkers
This axis aims to translate fundamental discoveries into personalized therapeutic strategies. It relies on the identification of molecular targets, the development of rational therapeutic combinations, and the validation of biomarkers to stratify patients and optimize their management.
Sub-axis 3.1: Targeting high-risk clones
Targeting TP53-mutated clones in myelodysplastic syndromes and acute myeloid leukemias
Contact : Bochra Mlayah, Nabih Maslah, Pierre Fenaux
Sub-axis 3.2: Biomarkers and patient stratification
Functional role of the LNK (SH2B3) adapter in patients with triple-negative thrombocythemia
Contact : Laura Velazquez, Bruno Cassinat
Functional in vitro analysis of JAK2 missense variants (Axis 1 / Axis 3 interface)
Contact : Diego Elrio, Nelly Bosselut, Bruno Cassinat, Emmanuelle Verger
Sub-axis 3.3: Rational therapeutic combinations
Combined pro-senescence and senolytic strategy in myeloproliferative neoplasms (Axis 1 / Axis 3 interface)
Contact : Nabih Maslah, Duanya Liu
Targeting TP53-mutated clones in myelodysplastic syndromes and acute myeloid leukemias
Contact : Bochra Mlayah, Nabih Maslah, Pierre Fenaux
Team members
Team alumni
Celine Aoun
Duanya Liu
Elodie Lesteven
Nabih MASLAH
Panhong Gou
Publications
2025 Nature Communications
JAK2 inhibition mediates clonal selection of RAS pathway mutations in myeloproliferative neoplasms
Nabih Maslah, Nina Kaci, Blandine Roux, Gabriela Alexe, Raphael Marie, Hélène Pasquer, Emmanuelle Verger, Rafael Daltro De Oliveira, Cécile Culeux, Bochra Mlayah, Nicolas Gauthier, Fanny Gonzales, Lin-Pierre Zhao, Saravanan Ganesan, Panhong Gou, Frank Ling, Juliette Soret-Dulphy, Nathalie Parquet, William Vainchenker, Emmanuel Raffoux, Rose Ann Padua, Stéphane Giraudier, Caroline Marty, Isabelle Plo, …Lina Benajiba
View2024 JCI Insight
Comprehensive analysis of mesenchymal cells reveals a dysregulated TGF-β/WNT/HOXB7 axis in patients with myelofibrosis
Saravanan Ganesan, Sarah Awan‑Toor, Fabien Guidez, Nabih Maslah, Rifkath Rahimy, Céline Aoun, Panhong Gou, Chloé Guiguen, Juliette Soret, Odonchimeg Ravdan, Valeria Bisio, Nicolas Dulphy, Camille Lobry, Marie‑Hélène Schlageter, Michèle Souyri, Stéphane Giraudier, Jean‑Jacques Kiladjian, Christine Chomienne, Bruno Cassinat
View2024 Journal of Cellular and Molecular Medicine
JAK2V617F-dependent down regulation of SHP-1 expression participates in the selection of myeloproliferative neoplasm cells in the presence of TGF-β
Céline Aoun, Nabih Maslah, Saravanan Ganesan, Norman Salomao, Romane Gendron, Sarah Awan Toor, Gil Letort, Panhong Gou, Mélina Bonnamy, Véronique Parietti, Jean‑Jacques Kiladjian, Stephane Giraudier, Bruno Cassinat
View2024 British Journal of Haematology
Targeting the redox vulnerability of acute myeloid leukaemia cells with a combination of auranofin and vitamin C
Zhiliang Hei, Shujun Yang, Guifang Ouyang, Jolimar Hanna, Michel Lepoivre, Tony Huynh, Lorea Aguinaga, Bruno Cassinat, Nabih Maslah, Mickaël Bourge, Marie‑Pierre Golinelli‑Cohen, Olivier Guittet, Cindy Vallières, Laurence Vernis, Pierre Fenaux, Meng‑Er Huang
View
